Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS EIF4E Rx + docetaxel + prednisone
- Development stage
- Unknown
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen of three drugs: - **ISIS EIF4E Rx** is an antisense oligonucleotide targeting the eukaryotic translation initiation factor 4E (eIF4E), developed by Ionis Pharmaceuticals (formerly known as ISIS Pharmaceuticals). The drug inhibits translation of eIF4E mRNA and is being investigated as a targeted therapy for cancer. - **Docetaxel** is a small molecule taxane-class chemotherapeutic agent that promotes microtubule stabilization, inhibiting cell division and inducing apoptosis, widely used in solid tumors including metastatic prostate cancer. - **Prednisone** is a synthetic glucocorticoid steroid used for its anti-inflammatory and immunosuppressant effects; in prostate cancer, it also suppresses adrenal androgen production and provides symptom palliation. This combination represents an experimental regimen studied especially in castration-resistant prostate cancer, based on the addition of ISIS EIF4E Rx to the established docetaxel plus prednisone backbone.
- Other names
- antisense oligonucleotide targeting eIF4E + docetaxel + prednisone
02
Targets
TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)EIF4E (Eukaryotic translation initiation factor 4E)
Beyond the preview
Go deeper on ISIS EIF4E Rx + docetaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS EIF4E Rx + docetaxel + prednisone.